Postoperative pain is a common form of acute pain that has been treated commonly by local anesthetics through regional nerve blocking. In this study, a series of experiments were conducted using rats to investigate the pharmacokinetic, distribution, and efficacy of a temperature responsive hydrogel-based drug delivery device (PF-72) containing ropivacaine (0.75%) for extended relief of postoperative pain by allowing the prolonged release of ropivacaine. When the ropivacaine was administered using PF-72, its concentration-time curve (AUC last ) and peak concentration (C max ) were 577.0 h*ng/mL and 271.9 ng/mL, respectively. In contrast when the ropivacaine solution was administered using saline solution, its AUC last and C max were 982.8 h*ng/mL and 423.6 ng/mL, respectively. In the tissue distribution study, the peak concentration and mean area under the curve of the ropivacaine in injection area (target tissue) were found about 2-fold higher in the case of PF-72 compared with the case of conventional ropivacaine solution. These results clearly demonstrate the capability of PF-72 hydrogel to retain the ropivacaine at the injection site for an extended period. Effective extended (at least 24 h) pain relief of ropivacaine administered using PF-72 was found in the pharmacodynamic study of prolonged analgesic effect. The results of this study indicated that local drug delivery by PF-72 hydrogel formulation may be an effective method to achieve extended relief of pain. Other advantages of ropivacaine administration using PF-72 include reduced systemic side effects and high localization of a drug in target tissues.
Introduction
Surgery is an essential modality to treat a variety of diseases. Although it is in general an expensive procedure with potential risks of complications that may be fatal in some cases, new surgical procedures have been developed and used frequently in clinics. The yearly number of major surgical procedures estimated in a study supported by WHO as a part of the Safe Surgery Saves Lives project was approximately 234 million throughout the world (Weiser et al., 2008) . Approximately 70 million surgical procedures are conducted annually in the United States while about half of them are performed as an inpatient procedure (Cullen et al., 2009; Hall et al., 2010) .
Acute pain present in a patient after surgery has been recognized to be one of the main postoperative adverse outcomes causing distress to patients (Sutters and Miaskowski, 1997) , prolonged hospital stays (Chung, 1995) and the higher incidence of unanticipated admissions after surgery (Fortier et al., 1998) . Another risk of persistent postsurgical pain is correlated with the risk of developing chronic pain that may reduce the quality of life significantly (Kehlet et al., 2006) . As such effective postoperative pain management is critical.
Conventional methods of postoperative administration of single or multiple analgesics via various routes (oral, intravenous, neuraxial, etc.) are well known for drug-related side effects (nausea, vomiting, pruritus, sedation, and respiratory depression) (Garimella and Cellini, 2013; Jin and Chung, 2001) . Multimodal techniques were recommended for effective perioperative pain management with less risk of side effects (Management, 2004 , Management, 2012 . Another method is the infiltration of local anesthetics (bupivacaine or ropivacaine at the surgical wound (Vinson-Bonnet et al., 2002) , which relieves the pain effectively but only for a short time period (< 12 h)).
The use of biodegradable and injectable drug delivery device is a viable option for more effective and safe management of acute https://doi.org/10.1016/j.ijpharm.2019.01.011 Received 26 October 2018; Received in revised form 9 December 2018; Accepted 4 January 2019 postoperative pain during the first few days by sustained release of local anesthetic administered to the painful surgical wound site. Such drug delivery systems can be made in the form of microspheres or temperature responsive hydrogels. For example, DepoFoam bupivacaine (bupivacaine extended-release liposome injection, EXPAREL) consisting of microscopic, spherical, and multi-vesicular liposomes was introduced by Pacira Pharmaceuticals, Inc. (Parsippany, NJ, USA). Wang et al. introduced nanoparticles made of polyethylene glycol-co-polylacticacid (PELA) as a drug delivery system to relieve postoperative pain for 3-5 days by prolonged administration of 10% ropivacaine (Wang et al., 2016) . A temperature responsive hydrogel with great potential as a drug delivery system for the effective management of postoperative pain for about 3 days was also introduced in the literature (Kim et al., 2015; Seol et al., 2013) . The purpose of this study was to investigate the safety and efficacy of a temperature responsive hydrogel-based drug delivery device (PF-72, TGel Bio, Inc., Ltd, Seoul, Korea) for its use to relieve the postoperative surgical pain for a few days by delivering 0.75% ropivacaine to the surgical wound as a part of preclinical studies required to get approval of Korean Food and Drug Administration for clinical trials.
Materials and methods
PF-72 (TGel Bio, Co., Ltd., Seoul, Korea) is a medical device under investigation of Korean Food and Drug Administration (KFDA) for its use to deliver ropivacaine to the surgical wound site in a sustained manner for extended relief of post-operative pain. PF-72 is a powder obtained from lyophilization of a reverse thermal hydrogel (Poloxamer 407 (20% wt/v) and Sodium Hyaluronate (0.5% wt/v) in sterilized physiological saline). When mixed with a drug solution, it becomes a drug containing reverse thermal hydrogel which is a viscous fluid at room temperature and becomes a gel containing a drug when injected into the target area in the body due to body temperature.
Specimens for the in-vitro and in-vivo tests described in the following sections were prepared in a form of a hydrogel made by injecting 0.75% ropivacaine solution into PF-72 bottle containing lyophilized powder. The ropivacaine solution (0.75% Nacain Injection) used in this study was a commercial product purchased from Huons Inc. (Sungnam City, Korea), and the ropivacaine containing hydrogel prepared in this way was used in the following in-vitro and in-vivo tests. The zero shear viscosity of the prepared specimen was 0.029 Pa·sec at 25°C and 35.7 Pa·sec at 37°C, and the gelation temperature was about 27.5°C. The viscosity of the prepared specimens (mean ± SD) was 417.5 (cPs) ± 7.8 at room temperature (22°C) and 20980.0 (cPs) ± 84.9, respectively. The complex modulus of the gel at physiological temperature was about 14 KPa.
Sterility test
Microbial growth of the hydrogel sample (the mixture of 0.75% ropivacaine and PF-72) were examined up to 14 days in sterility tests that were conducted in a GLP certified institute (Korea Testing & Research Institute, Gwacheon City, Korea) . Microbial growth in the test sample prepared using membrane filter technique and cultured only in the liquid thioglycolic acid medium but also in soybean casein digestive badge was observed in accordance with the Guide Line in the U.S. Pharmacopoeia 39, < 71 > Sterility Test. In addition, the pH of the hydrogel sample stored in a refrigerator (2-8°C) was measured using a pH meter (S220-BIO, Mettler Toledo, Columbus, Ohio, USA) at 0, 24, 48, and 72 h after storage.
In-vitro ropivacaine release test
To measure the drug release profile of ropivacaine from the PF-72, PF72 with 0.75% ropivacaine solution was dispersed in 15 mL of PBS (phosphate buffered saline, pH 7.4) and put into a dialysis bag (MWCO: 12 K-14 K Da, Spectrum®, Rancho Dominquez, CA, USA), which was immersed in 15 mL of PBS (pH 7.4). The dialysis bag was placed in a shaking water bath maintained at 37°C and was shaken horizontally at 100 rpm. At predetermined time intervals, 1.5 mL of aliquots of release medium (PBS) were withdrawn and the total release medium was replaced with 15 mL of fresh PBS to maintain the sink condition. The quantification of released ropivacaine was determined by reverse phase-high performance liquid chromatography (RP-HPLC) using a ZORBAX Eclipse XDB C18 column (4.6 mm × 250 mm, 5 µm) and an acetonitrile/pH 8.0 buffer (60:40, v/v) mobile phase over 10 min at a flow rate of 1.2 mL/min. The eluent was monitored by UV absorption at 240 nm.
Pharmacokinetics analysis
An in-vivo study was conducted in the GLP certified laboratory in Nonclinical Research Institute, Chemon, Inc. (Yongin-si, Korea) using male Sprague-Dawley rats (312-350 g). PF-72 hydrogel with 0.75% ropivacaine (dose: 4 mg/kg) was injected into a subcutaneous area of an animal in the experimental group (PF-72, n = 5) while 0.75% ropivacaine solution was injected into an animal in the control group (Nacain, n = 5). Blood (0.4 mL) was withdrawn before ropivacaine injection and at specific time points of 0.5, 1, 2, 4, 6, 8, 12, 24, 36, 48 , and 72 h after drug administration. The blood sample was immediately was stabilized with 4 μL of heparin solution (sodium heparin 500 IU/mL), and the plasma was collected by centrifugation of the stabilized specimen for 10 min at 3000g using a refrigerated centrifuge. The collected plasma was stored at −50°C until analysis. The plasma concentration of ropivacaine was measured by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS) (Wang et al., 2016) . The pharmacokinetic parameters of peak concentration (C max ), time to peak concentration (T max ), elimination half time (t 1/2 ), and area under the concentration-time curve (AUC last ) were calculated using Phoenix™ WinNonlin® (ver. 6.2, Pharsight) based on the non-compartment analysis. The difference in these parameters between the Nacain and PF-72 groups was tested using Student t-test (SPSS version 22).
Distribution of ropivacaine in various tissues
An in-vivo study was conducted in the GLP certified laboratory in KRICT (Daejeon, Korea) using male SD rats (220-230 g). PF-72 gel with 0.75% ropivacaine (dose: 4 mg/kg) was injected into a subcutaneous area of an animal in the experimental group (PF-72, n = 18) while 0.75% ropivacaine solution was injected into an animal in the control group (Nacain, n = 18). Blood (0.4 mL) was withdrawn before ropivacaine injection and at specific time points (1, 4, 8, 24, 48 , and 72 h). The plasma, heart, liver, lung, GI tract, brain, kidney, and internal skin of injection area were collected after 1, 4, 8, 24, 48, and 72 h after injection. The tissues except plasma were added to three volumes phosphate buffered solution per tissue weight, homogenized, and stored at −20°C until being analyzed for ropivacaine using LC-MS/MS. The amount of ropivacaine in the tissues was quantified using liquid chromatography coupled with tandem mass spectrometry consisting of an Agilent 1200 series HPLC (Agilent Technologies, Santa Clara, CA, USA) and QTRAP API 4000 (AB SCIEX, Foster City, CA, USA) mass spectrometer equipped with a turbo electrospray interface. Chromatographic separation of ropivacaine was achieved on a Phenomenex Kinetex® C 18 column (2.1 mm × 50 mm, 2.6 µm) with a Security Guard C 18 guard column (Torrance, CA, USA) maintained at 40°C. The mobile phase consisted of water (A) and ACN (B) with 0.1% formic acid, respectively. The HPLC gradient condition (flow rate, 0.30 mL/min; total run time, 5.00 min; injection volume, 5 µL) was performed as follows: initial 2% B for 0-0.30 min, 0.30-1.00 min, B 2 → 98%; 1.0-1.50 min, B 98 → 98%; 1.50-2.10 min, B 98 → 2%; 2.10-5.00 min, 2 → 2%. The optimized MS/ MS conditions were as follows: ion spray voltage, 5500 V; source temperature, 550°C; curtain gas, 10 psi; nebulizing gas (GS1), 50 psi; heating gas (GS2), 50psi, declustering potential (DP), 6.00 V; collision energy (CE), 29.0 V; entrance potential (EP), 10.0 V; and collision-exit potential (CXP), 22.0 V. Quantification of ropivacaine was performed on multiple reaction monitoring (MRM) of the transition of m/z 275.2 → 126.1. Data analysis was performed using Analyst Software version 1.4.2. (AB Sciex, Foster City, CA, USA).
All results are expressed as means ± standard deviation (S.D.). The significance of the difference between two groups was analyzed using Student's t-test. A value of p < 0.05 and 0.01 was considered to indicate statistical significance.
Pharmacodynamic analysis
An in-vivo study was conducted in the GLP certified laboratory in Nonclinical Research Institute, Chemon, Inc. (Yongin-si, Korea) using male Sprague-Dawley rats (306-350 g). Animals were randomly assigned to one of the four groups. Animals in normal control (Nor control) were received with no surgery and drug treatment. In order to produce a postoperative pain model, all animals in the remaining three groups (n = 6 for each group) received the surgery in the left hind paw following the method described in a previous study (Wang et al., 2016) . Immediately after the surgery, a testing material of 200 μL was subcutaneously injected into the vicinity of the sciatic nerve in the left ankle. The testing materials were: PF-72 hydrogel with no drug (Hydrogel), 0.75% ropivacaine solution (Nacain), and PF-72 hydrogel containing 0.75% ropivacaine (PF-72). The paw withdrawal threshold (PWT) was measured to assess mechanical hypersensitivity using von Frey filament (1, 1.4, 2, 4, 6, 8, 15, 26, 60 g ). Briefly, the rat was placed under a transparent plastic dome (28 × 2 × 10 cm) on a metal mesh floor and von Frey filament applied to the plantar surface of the foot. A von Frey filament was applied for 3-4 s to each hind paw while the filament was bent. The 50% withdrawal threshold was determined using the up-down method (Chaplan et al., 1994) while starting with a force of 2.0 g (4.31 mN) and continuing until a withdrawal response occurred or a force of 5.10 g was reached. Stimuli were presented at intervals of several seconds. Interpolation of the 50% threshold was carried out according to the method of Dixon (Dixon, 1980) . Von Frey test was performed before surgery and postoperatively at specific times (1, 4, 24, 48, and 72 h). The measured PWT values were analyzed statistically using nonparametric multiple comparison procedures in SPSS Statistics 22 for medical science.
Pharmacokinetic and Pharmacodynamic properties of the ropivacaine containing hydrogel were tested in a GLP certified laboratory in Nonclinical Research Institute, Chemon, Inc. (Yongin-si, Korea). In addition, the distribution of ropivacaine in various tissues was investigated in Korea Research Institute of Chemical Technology (KRICT, Daejeon City, Korea). For these experiments, hydrogel solution containing ropivacaine was prepared by adding 0.75% (w/v) ropivacaine solution (Nacain Injection, Huons Co., Ltd., Sungnam, Korea).
The investigations were approved by the Animal Care and Use Committee of Chemon, Inc. and KRICT. All animal experiments were conducted in compliance with the Guiding Principles for the Care and Use of Laboratory Animals of both institutes. Male Sprague-Dawley (SD) rats were housed two per cage with relative humidity (55 ± 15%) in a 12 h light-dark cycle at room temperature (23 ± 3°C). All animals were allowed to access the food and water freely.
Results
Various in-vitro and in-vivo studies were performed as part of the preclinical test of using PF-72 for delivering 0.75% ropivacaine to the target site. The following results of all tests were used to get approval of Korean Food and Drug Administration for clinical trials of PF-72 as a device to achieve prolonged relief of postoperative pain by releasing the 0.75% ropivacaine directly to the painful surgical wound sites in a controlled manner.
Sterility test
No microbial growth in the hydrogel prepared by injecting 0.75% ropivacaine solution into PF-72 was observed for 14 days when cultured in liquid thioglycolic acid medium as well as in soybean casein digestive badge. The pH of the hydrogel sample was: 6.27 at 0 h, 6.19 at 24 h, 6.30 at 48 h, and 6.16 at 72 h.
In-vitro ropivacaine release test
All ropivacaine was released from a saline solution within 4 h (Free ropivacaine in Fig. 1 ). In contrast, ropivacaine release from the hydrogel was delayed over time (Ropivacaine with PF-72 in Fig. 1 ).
In-vivo tests
A total of three in-vivo tests were conducted using rats to investigate the pharmacokinetics, localization, and pharmacodynamics characteristics of the mixture of PF-72 and 0.75% ropivacaine. In all tests, no external signs of inflammatory reactions, such as redness, seepage, warmth, or edema around injection sites were observed in any animals used in these three in-vivo tests performed in this study. The results of these in-vivo tests are as follows:
Pharmacokinetic analysis
Pharmacokinetic properties of ropivacaine were evaluated when ropivacaine was administered subcutaneously with free form (Nacain) or the hydrogel (PF-72). As shown in Fig. 2 and Table 1 , AUC last and C max with the gel were 577.0 h*ng/mL and 271.9 ng/mL, respectively, Fig. 1 . In-vitro drug Release profile of free ropivacaine (0.75% Nacain Injection) and ropivacaine with PF-72. Fig. 2 . Ropivacaine concentration in blood over time.
K.S. Oh et al. International Journal of Pharmaceutics 558 (2019) 225-230 whereas those with free form were 982.8 h*ng/mL and 423.6 ng/mL, respectively. Fig. 3 shows temporal changes in tissue concentration of ropivacaine following subcutaneous administration using PF-72 hydrogel (PF-72) or saline solution (Nacain). The ropivacaine concentrations in all Fig. 3 . Tissue concentration-time profile of ropivacaine after subcutaneous administration of 4 mg/kg. (Mean ± SD, n = 5). The significant difference from Group 1, *P < 0.05, **P < 0.01, and ***P < 0.001. tested tissues of Nacain group except the injection area were higher than those of PF-72 group at 1 h after administration while there were no significant differences at all times after 1 h. As a result as shown in Table 2 , the total exposure of ropivacaine (AUC last ) of PF72 group was significantly lower than that of the control, Nacain group, in all tissues except for GI tract and kidney. On the other hand, the peak concentration and mean area under the curve in the injection area, the target tissue, of PF-72 group were about 2-fold higher than those of solution group, showing that the PF-72 hydrogel held the ropivacaine at the injection site more effectively than the saline solution.
Ropivacaine distributions in various tissues

Pharmacodynamic analysis
Paw withdrawal threshold (PWT) values of the group PE (injection of PF-72 only) were significantly lower than those of group Nor control, indicating the surgery-induced painful condition. PWT values of the experimental group (PF-72) were significantly higher than those of PE group at 1, 4, and 24 h and maintained the PWT values higher at 48 and 72 h although the difference was not statistically significant (Fig. 4) . PWT values of the control group (Nacain) were the greatest at 1h but decreased to the level of the sham control group (Hydrogel) at 4 h and demonstrated changes similar to those of Hydrogel group PE for the rest of observation period up to 72 h (Fig. 4) .
Discussion
A series of preclinical tests were conducted in this study in order to investigate pharmacokinetic, distribution, and efficacy of a temperature responsive hydrogel-based drug delivery device TGel Bio, Inc., Ltd, Seoul, Korea) for its use to relieve the postoperative surgical pain for a few days by delivering 0.75% ropivacaine to the surgical wound. PF-72 was developed based on the use of a temperature responsive hydrogel (consisting of Poloxamer 407 and sodium hyaluronate) whose characteristics for a drug delivery system were investigated in previous studies. The temperature responsive reverse thermal behaviors and injectability of the hydrogel were demonstrated by Lee et al. (2010) . In addition, a couple of in-vivo studies confirmed the excellent biocompatibility and sustained drug release characteristic of the hydrogel (Kim et al., 2015; Seol et al., 2013) . In previous studies, however, 1.25% bupivacaine was used for their tests. The delivery of 0.75% ropivacaine using the hydrogel as in PF-72 has not been investigated yet.
The results of tests done in this study showed great potential of PF-72 for its clinical application. For, example, the sterility test results confirmed the sterility of the system. In-vitro drug release test demonstrated faster ropivacaine release from the hydrogel than bupivacaine release observed in the previous study (Seol et al., 2013) , particularly in 24 h. However, it may be an advantage for the initiation of effective relief of surgical wound pain in the early postoperative period (e.g., within 12 h after surgery).
Furthermore, no signs of inflammatory reactions to the PF-72 hydrogel were observed in any animals used in 3 in-vivo tests, indicating excellent biocompatibility of the hydrogel as shown in previous studies (Kim et al., 2015; Seol et al., 2013) . The results of the pharmacokinetic study showed that the ropivacaine concentration in blood plasma when administered using PF-72 was 60% of that in free form (Nacain Injection), indicating the retention of ropivacaine in the hydrogel at the delivery site longer time. Effective pain relief for 24 h or longer after surgery was observed in the pharmacodynamics test when administering ropivacaine through PF-72. Significantly higher concentration of ropivacaine at the injection site but significantly less concentration in blood plasma and other organs found in the distribution test clearly demonstrated excellent localization and slow drug release capabilities of PF-72 hydrogel. Similar results were found in Wang et al.'s pharmacokinetic study of ropivacaine released from nanoparticles made of polyethylene glycol-co-polylactic-acid (PELA) (Wang et al., 2016) .
The results of the pharmacodynamic study also demonstrated effective pain relief of ropivacaine administered using PF-72 for 24 h or longer. This pain relief period of 24 h is significantly longer than the pain relief for shorter than 10-12 h obtained by the administration of ropivacaine via wound infiltration but may be too short for effective relief of postoperative pain sufficiently long. However, the results of another rat in-vivo study conducted in Korea University (unpublished data) showed an effective pain relief for at least 48 h after surgery when the same PF-72 hydrogel containing 0.75% ropivacaine was administered directly into the surgical site made in the back of the rats, not around the sciatic nerve roots.
Such difference in the duration of pain relief may occur because the effectiveness of ropivacaine may vary depending upon the type of nerves (e.g., nociceptors vs. nerve roots). The administration of ropivacaine using PF-72 hydrogel into the surgical site may be able to provide effective pain relief much longer than 24 h.
In the study of ropivacaine distribution in various tissues, the administration of ropivacaine via PF-72 was also found to result in a significantly higher concentration at the injection site but significantly less concentration of ropivacaine in various organs than the injection of ropivacaine solution. This result clearly demonstrated the capability of PF-72 to localize the drug at the injection site with minimum risk of side effect in the other tissues and organs.
As such, the results of this study showed excellent safety and effective long-term pain relief of ropivacaine administered using PF-72. Ropivacaine is a local anesthetic widely used in clinics not only because of its efficacy well known similar to bupivacaine but also because of its lower propensity for a motor block. The administration of ropivacaine using PF-72 via wound infiltration may be an ideal method to manage the postoperative pain for a few days with minimum use of analgesics. The clinical application of PF-72 containing 0.75% ropivacaine, however, requires further clinical tests following the protocols confirming the regulatory agency's guidelines.
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